Meet the drug manufacturer taking the FDA to task for the opioid crisis
Francis Collins, then head of the powerful National Institutes of Health, got right to the point. In a closed-door meeting with pharmaceutical manufacturer Edwin Thompson, Collins demanded Thompson back off his campaign to drastically cut back the use of prescription opioids for chronic, long-term pain. According to Thompson, Collins admitted healthcare regulators knew there was no science showing opioids were effective for anything but acute, short-term incidents. There was at the same time credible research showing the longer a patient remained on opioids, the greater the risk of addiction. Some studies even suggested long-term use increased pain sensitivity. But on that day in 2019, none of that mattered to Collins.
